Publications by authors named "Yunchun Long"
Article Synopsis
- The RATIONALE-305 trial found that using tislelizumab with chemotherapy is more effective for treating advanced gastric cancer than using chemotherapy alone.
- A cost-effectiveness analysis showed that this combination therapy resulted in a gain of 0.31 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio (ICER) of $33,876.38 per QALY, which is below China's willingness-to-pay threshold.
- The study concluded that tislelizumab with chemotherapy is a cost-effective treatment option in the Chinese healthcare context for advanced gastric cancer and gastroesophageal junction adenocarcinoma.
Article Synopsis
- The CAPSTONE-1 trial showed that adebrelimab-based immunotherapy provides better survival rates than chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC).
- A cost-effectiveness analysis using a survival model indicated that while adebrelimab resulted in more quality-adjusted life-years (QALYs), its high cost led to an unfavorable incremental cost-effectiveness ratio (ICER) of US$163,893/QALY.
- Overall, the study concluded that using adebrelimab with chemotherapy is not a cost-effective treatment option for ES-SCLC within the Chinese healthcare system.
Objective: The ASTRUM-007 study confirmed the significant efficacy and safety of serplulimab plus chemotherapy for patients with locally advanced/metastatic, programmed cell death-ligand 1 positive oesophageal squamous cell carcinoma (OSCC). The economics of this regimen, however, is unclear. Therefore, this study aimed to evaluate the cost-effectiveness of adding serplulimab to chemotherapy for the treatment of advanced OSCC from the perspective of the Chinese healthcare system.
View Article and Find Full Text PDFObjective: The ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP came at high costs, and its economy is not clear. Therefore, this study aimed to evaluate the cost-effectiveness of SEP from the perspective of the Chinese healthcare system.
View Article and Find Full Text PDFArticle Synopsis
- The CHOICE-01 trial demonstrated that toripalimab combined with chemotherapy improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) lacking driver genes, prompting a study on its cost-effectiveness in the Chinese healthcare system.
- A model was created to evaluate the costs and health outcomes of adding toripalimab to first-line chemotherapy, using data from the CHOICE-01 trial and focusing on direct medical expenses.
- Findings indicated that toripalimab added an extra cost of $21,052 but offered better health outcomes (0.71 more QALYs), making it cost-effective compared to standard chemotherapy based on the current willingness-to-pay threshold.
Objective: To evaluate the economics of sugemalimab plus chemotherapy in the first-line treatment of metastatic non-small cell lung cancer, and to provide a reference for the formulation of relevant medical insurance policies and rational drug use.
Methods: From the perspective of the Chinese health system, a three-state partitioned survival model was constructed based on data from a phase III randomized clinical trial (GEMSTONE 302) to evaluate the cost-utility of sugemalimab plus chemotherapy compared with chemotherapy in first-line treatment of metastatic non-small cell lung cancer. Model results were expressed as total cost, life years, quality-adjusted life years, and incremental cost-effectiveness ratio.